|Main uses||Kidney transplant|
|Side effects||Constipation, nausea, abdominal pain, heart burn, high potassium, low potassium, headache, swelling, fever, shortness of breath, trouble sleeping|
|Elimination half-life||7.2 days|
|Chemical and physical data|
|Molar mass||143801.68 g·mol−1|
Basiliximab, sold under the brand name Simulect, is a medication used to prevent rejection following a kidney transplant. It is used together with ciclosporin and corticosteroids. It is given by injection into a vein.
Common side effects include constipation, nausea, abdominal pain, heart burn, high potassium, low potassium, headache, swelling, fever, shortness of breath, and trouble sleeping. Other side effects may include infections and anaphylaxis. Use in pregnancy is not recommended. It is a monoclonal antibody that attaches to CD25 on T cells and thus blocks interleukin-2.
Basiliximab was approved for medical use in the United States and Europe in 1998. In the United Kingdom a typical dose costs about £840 as of 2021. In the United States this amount costs about 4,100 USD.
Basiliximab is an immunosuppressant agent used to prevent immediate transplant rejection in people who are receiving kidney transplants, in combination with other agents. It has been reported that some cases of lichen planus have been successfully treated with basiliximab as an alternative therapy to cyclosporin. No short-term side effects have been reported.
It is given as a dose of 20 mg within two hours of surgery followed by 20 mg 4 days later.
Mechanism of action
Basiliximab competes with IL-2 to bind to the alpha chain subunit of the IL2 receptor on the surface of the activated T lymphocytes and thus prevents the receptor from signaling. This prevents T cells from replicating and also from activating B cells, which are responsible for the production of antibodies, which would bind to the transplanted organ and stimulate an immune response against the transplant.
- "Basiliximab Monograph for Professionals". Drugs.com. Archived from the original on 26 August 2019. Retrieved 8 January 2022.
- BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 891. ISBN 978-0857114105.
- "Simulect". Archived from the original on 11 January 2022. Retrieved 8 January 2022.
- "Simulect Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 24 January 2021. Retrieved 8 January 2022.
- MedlinePlus. Last Revised - June 15, 2012 Basiliximab Injection Archived 2016-07-05 at the Wayback Machine
- Katsambas AD, Lotti TM (2003). European handbook of dermatological treatments (2nd ed.). p. 291. ISBN 3-540-00878-0.
- Hardinger KL, Brennan DC, Klein CL (July 2013). "Selection of induction therapy in kidney transplantation". Transplant International. 26 (7): 662–72. doi:10.1111/tri.12043. PMID 23279211. S2CID 3296555.
- "Basiliximab label" (PDF). Archived (PDF) from the original on 2017-02-22. Retrieved 2021-02-04.
- Waldmann TA (March 2003). "Immunotherapy: past, present and future". Nature Medicine. 9 (3): 269–77. doi:10.1038/nm0303-269. PMID 12612576. S2CID 9745527. Archived from the original on 2021-04-13. Retrieved 2021-02-04.